Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| DRMA | 8-K | neutral | 4/10 | Dermata Therapeutics announced via an 8-K that its first commercial product, Tome Foundational Treatment, will launch on | Aug 5, 2026 |
| SPRC | 6-K | neutral | 5/10 | SciSparc's subsidiary NeuroThera Labs announced the initiation of a Phase IIb clinical trial site at Yale Child Study Ce | Aug 5, 2026 |
| AIM | 8-K | mixed | 6/10 | AIM ImmunoTech mutually terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026, cl | Aug 5, 2026 |
| PHGE | PRESS-RELEASE | bearish | 5/10 | BiomX acquired a 10% stake in Motomea for $50,000 cash plus 1.3M restricted shares (pending NYSE approval), gaining acce | Aug 5, 2026 |
| ALT | PRESS-RELEASE | neutral | 1/10 | Altimmune, Inc announced it will report its Q2 2026 results on August 12, 2026. | Aug 5, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three C-suite insiders at Nurix Therapeutics (CSO, CLO, CFO) sold a total of $461K in open-market shares over a 7-day wi | Aug 5, 2026 |
| KURA | PRESS-RELEASE | neutral | 1/10 | Kura Oncology, Inc. announced it will report its Q2 results on August 12, 2026. | Aug 5, 2026 |
| IMRX | PRESS-RELEASE | neutral | 5/10 | Immuneering reported Q2 2026 net loss of $17.3M ($0.27/share), wider than the $14.4M loss in Q2 2025, driven by increase | Aug 5, 2026 |
| BCTXL | PRESS-RELEASE | bullish | 5/10 | BriaCell received FDA clearance of its Investigational New Drug (IND) application for Bria-PROS+, a next-generation pers | Aug 5, 2026 |
| RPRX | 8-K | bullish | 6/10 | Royalty Pharma reported Q2 2026 results with Portfolio Receipts of $773M (+6% YoY) and Portfolio Cash Flow per diluted s | Aug 5, 2026 |
| IMRX | 8-K | neutral | 5/10 | Immuneering reported Q2 2026 results with a net loss of $17.3M ($0.27/share), widening from $14.4M ($0.40/share) in Q2 2 | Aug 5, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 | Aug 5, 2026 |
| ELAN | 8-K | bullish | 7/10 | Elanco reported Q2 2026 adjusted EPS of $0.34, a 26.5% beat vs. the $0.27 consensus, on revenue of $1.368B (8% organic c | Aug 5, 2026 |
| CMPS | 8-K | neutral | 5/10 | Compass Pathways reported Q2 2026 results with a net loss of $1.88 per share, a wider loss vs $0.41 in Q2 2025, driven b | Aug 5, 2026 |
| RXRX | 8-K | mixed | 6/10 | Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 | Aug 5, 2026 |
| UTHR | 8-K | mixed | 6/10 | United Therapeutics reported Q2 2026 revenue of $783.3M, down 2% YoY and below the $804.6M consensus, while diluted EPS | Aug 5, 2026 |
| PRGO | 8-K | mixed | 6/10 | Perrigo reported Q2 2026 adjusted EPS of $0.50, beating consensus of $0.35 by 42.9%, but revenue declined 3.2% YoY to $1 | Aug 5, 2026 |
| ETON | PRESS-RELEASE | bullish | 7/10 | Eton Pharmaceuticals licensed U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals, a late-stage rare | Aug 5, 2026 |
| ONC | 8-K | bullish | 7/10 | BeOne Medicines reported Q2 2026 revenue of $1.71B (+30% YoY) and GAAP diluted EPS of $2.05/ADS, with raised FY2026 reve | Aug 5, 2026 |
| INCY | CLUSTER | neutral | 3/10 | The CSO and President of R&D at Incyte sold a combined $2.16M in open-market shares in the week following the Q2 2026 ea | Aug 5, 2026 |
| XERS | CLUSTER | neutral | 2/10 | Two non-C-suite insiders at Xeris Biopharma sold a combined $254K in open-market transactions over a 7-day window. The t | Aug 4, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | CEO Derek Maetzold and CCO Tobin Juvenal sold a combined ~$286K in open-market sales over a 2-day window (July 31–Aug 3) | Aug 4, 2026 |
| ABBV | COURT-RULING | neutral | 1/10 | The U.S. District Court for the Eastern District of Pennsylvania granted AbbVie's motion to dismiss the plaintiff's clai | Aug 4, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Three C-suite insiders at Nurix Therapeutics (CFO, CSO, CLO) sold a total of ~$515K in open-market sales over a 7-day wi | Aug 4, 2026 |
| ALZN | 3 | neutral | 2/10 | Hyperscale Data, Inc. (HSD) filed a Form 3 initial statement of beneficial ownership for Alzamend Neuro (ALZN), disclosi | Aug 4, 2026 |
| GRCE | PRESS-RELEASE | neutral | 5/10 | Grace Therapeutics announced a ~$10M private placement (4,761,904 shares at $2.10/share) with new and existing fundament | Aug 4, 2026 |
| ATTO | 3 | neutral | 2/10 | David Kroin, Deep Track Capital, LP, and Deep Track Biotechnology Master Fund, Ltd. filed a Form 3 initial statement of | Aug 4, 2026 |
| ATTO | PRESS-RELEASE | neutral | 5/10 | Attovia Therapeutics priced its upsized IPO of 17M shares at $17.00/share, raising $289M in gross proceeds. The company | Aug 4, 2026 |
| ATTO | 3 | neutral | 2/10 | Redmile Group, LLC, Jeremy Green, and Redmile Biopharma Investments III, L.P. filed a Form 3 initial statement of benefi | Aug 4, 2026 |
| MPLT | CLUSTER | bullish | 7/10 | A mixed insider cluster at MapLight Therapeutics shows a 10% owner (Catalyst4, Inc.) making a $13M open-market purchase | Aug 4, 2026 |